Published online before print April 19, 2007

This Article Full Text (Rapid PDF) All Versions of this Article: ajpath.2007.060720v1 170/6/2100    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bonfil, R. D. Articles by Cher, M. L. Search for Related Content PubMed Articles by Bonfil, R. D. Articles by Cher, M. L.

Copyright © 2007 American Society for Investigative Pathology
American Journal of Pathology, doi:10.2353/ajpath.2007.060720

Accepted for publication February 27, 2007.

Article

Prostate Cancer-Associated Membrane Type 1-Matrix Metalloproteinase. A Pivotal Role in Bone Response and Intraosseous Tumor Growth

R. Daniel Bonfil^*, Zhong Dong^*, J. Carlos Trindade Filho^*, Aaron Sabbota^*, Pamela Osenkowski, Sanaa Nabha^*, Hamilto Yamamoto^*, Sreenivasa R. Chinni^*, Huiren Zhao, Shahriar Mobashery, Robert L. Vessella, Rafael Fridman, and Michael L. Cher^*@

From the Departments of Urology* and Pathology, Wayne State University School of Medicine and The Barbara Ann Karmanos Cancer Institute, Detroit, Michigan; the Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana; and the Department of Urology, University of Washington, Seattle, Washington

^@ To whom correspondence should be addressed. E-mail: mcher{at}med.wayne.edu.

	Abstract

Membrane type 1-matrix metalloproteinase (MT1-MMP) is a major mediator of collagen I degradation. In human samples, we show that prostate cancer cells in skeletal metastases consistently express abundant MT1-MMP protein. Because prostate cancer bone metastasis requires remodeling of the collagen-rich bone matrix, we investigated the role of cancer cell-derived MT1-MMP in an experimental model of tumor-bone interaction. MT1-MMP-deficient LNCaP human prostate cancer cells were stably transfected with human wild-type MT1-MMP (MT1wt). Furthermore, endogenous MT1-MMP was down-regulated by small interfering RNA in DU145 human prostate cancer cells. Intratibial tumor injection in severe combined immunodeficient mice was used to simulate intraosseous growth of metastatic tumors. LNCaP-MT1wt cells produced larger osseous tumors than Neo control cells and induced osteolysis, whereas DU145 MT1-MMP-silenced transfectants induced osteogenic changes. In vitro assays showed that MT1wt overexpression enhanced collagen I degradation, whereas MT1-MMP-silencing did the opposite, suggesting that tumor-derived MT1-MMP may contribute directly to bone remodeling. LNCaP-MT1wt-derived conditioned medium stimulated in vitro multinucleated osteoclast formation. This effect was inhibited by osteoprotegerin, a decoy receptor for receptor activator of nuclear factor B ligand, and by 4-[4-(methanesulfonamido) phenoxy] phenylsulfonyl methylthiirane, an MT1-MMP inhibitor. Our findings are consistent with the hypothesis that prostate cancer-associated MT1-MMP plays a direct and/or indirect role in bone matrix degradation, thus favoring intraosseous tumor expansion.